PROCEPT BioRobotics Corporation (Nasdaq: PRCT), a leader in surgical robotics focused on urology, has announced its unaudited financial results for the second quarter of 2025. The company reported total revenue of $79.2 million, marking a 48% increase from the same period in 2024. U.S. revenue reached $69.6 million, a 46% rise, driven largely by new hospital customer system sales and increased handpiece revenue. The U.S. handpiece and consumable revenue grew by 58% to $43.1 million, while U.S. system revenue increased by 24% to $22.1 million. International revenue also saw significant growth, rising 69% to $9.6 million. The gross margin for the quarter improved to 65%, up from 59% in the prior year period, attributed to enhanced operational efficiencies and higher average selling prices of U.S. robotic systems. The company recorded a net loss of $19.6 million for the second quarter, an improvement from the $25.6 million loss in the same period the previous year. Adjusted EBITDA showed a loss of $8.0 million, compared to a loss of $17.9 million in the prior year period. Operating expenses increased to $73.9 million from $58.3 million, primarily due to expansion of the commercial organization and increased research and development as well as general and administrative expenses. Looking ahead, PROCEPT BioRobotics projects a full-year 2025 Adjusted EBITDA loss of approximately $35.0 million. As of June 30, 2025, the company had an install base of 595 robotic systems in the U.S.